STENOCARE / Investor relations / News archiveNews archive 30-06-2020STENOCARE is debt free 17-06-2020STENOCARE – Rights issue registered and warrants exercised 15-06-2020STENOCARE rights issue received subscriptions of DKK 117 million or 392% 09-06-2020STENOCARE: Status from Founders’ transactions to satisfy demand for subscription rights 09-06-2020STENOCARE founders to satisfy demand for subscription rights 27-05-2020STENOCARE – Today is the first day of subscribing for the share issue 18-05-2020STENOCARE – Today is the first day of trading on Nasdaq First North Growth Market Denmark 14-05-2020COMMUNIQUE FROM THE ANNUAL GENERAL MEETING OF STENOCARE 13-05-2020STENOCARE – First day of trading on NASDAQ FIRST NORTH GROWTH MARKET DENMARK will be 18 May 2020 11-05-2020STENOCARE founders to offer a free share for subscribers 11-05-2020RAISING UP TO 45 MILLION DKK FOR INTERNATIONAL ACCELERATION 11-05-2020DECISION TO LIST AND PUBLICATION OF PROSPECTUS 29-04-2020Notice to Annual General Meeting in STENOCARE A/S 16-03-2020Communiqué from extraordinary general meeting in STENOCARE A/S 11-03-2020STENOCARE signs agreement with new prominent supplier, PANAXIA and announces imminent product approval application filing 28-02-2020Notice to Extraordinary General Meeting in STENOCARE A/S 27-02-2020STENOCARE: New video regarding the profitable Year-End Report 2019 and the road ahead 14-01-2020STENOCARE: Notification of changes in major shareholding and increased holding of own shares. 13-01-2020STENOCARE enters final settlement agreement with CannTrust 19-12-2019STENOCARE sign strategic development partnership with Solural Pharma 13-11-2019STENOCARE and OWC Pharmaceutical Research Corp. to enter partnership to develop advanced medical cannabis products 07-11-2019STENOCARE sign supply agreement with Emerald Health Therapeutics Inc 31-10-2019STENOCARE CEO looks ahead after the first year as a listed company 30-09-2019STENOCARE successfully completes its first harvest without use of pesticides 19-09-2019STENOCARE terminates license agreement with CannTrust and prepares for new partnerships 05-09-2019Change in Board of Directors 20-08-2019Additional cultivation related issues identified at CannTrust 16-07-2019STENOCARE to establish the world’s first hybrid, in-door cultivation facility for production of premium medical cannabis at scale 11-07-2019STENOCARE receives new information from CannTrust that causes immediate quarantine on sales of products from current inventory 09-07-2019STENOCARE UNHARMED BY HEALTH CANADA’S AUDIT OF CANNTRUST 01-07-2019STENOCARE enters the Irish market with its own subsidiary 25-06-2019Danish cannabis cultivation commenced 24-05-2019STENOCARE A/S is ready with new medical cannabis product 23-05-2019STENOCARE A/S has been declared IPO of the Year 2018 16-05-2019Communique from the Annual General Meeting of STENOCARE A/S 01-05-2019Notice to Annual General Meeting in STENOCARE A/S 05-04-2019Shareholders in STENOCARE A/S nominate new member to the Board of Directors 29-03-2019Danish cannabis production due to start shortly 20-03-2019STENOCARE products are being used in clinical trials at Rigshospitalet Multiple Sclerosis Center 10-12-2018STENOCARE A/S on track with the planned offering of Medical Cannabis Capsules to offer Danish patients more choice in their treatment 30-11-2018STENOCARE A/S experiences positive demand and imports the second batch of medical cannabis oil products 29-10-2018Gemstone Capital ApS has decided to exercise 45,000 warrants 26-10-2018First day of trading in STENOCARE A/S shares on Spotlight Stock Market 12-10-2018STENOCARE A/S new share issue significantly oversubscribed 24-09-2018The subscription period in STENOCARE A/S’s new share issue begins today 21-09-2018STENOCARE A/S – the first medical cannabis IPO in Europe – has been approved for listing on Spotlight Stock Market
